7-isopropoxy-6-methoxy-3,4-dihydroisoquinoline | 86457-06-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢异喹啉
• 英文名称: 7-isopropoxy-6-methoxy-3,4-dihydroisoquinoline
• 英文别名: 6-Methoxy-7-propan-2-yloxy-3,4-dihydroisoquinoline
• CAS: 86457-06-9
• 化学式: C₁₃H₁₇NO₂
• 分子量: 219.283
• InChiKey: BEDOOZHQUQCJTM-UHFFFAOYSA-N

物化性质

• 沸点：
  343.6±42.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  30.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-isopropoxy-6-methoxy-3,4-dihydroisoquinoline 、 (S)-4-isopropyl-2-(o-tolyl)-4,5-dihydrooxazole 在 仲丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 4.25h， 以51%的产率得到(S)-7-isopropoxy-1-{2-[(S)-4-isopropyl-4,5-dihydrooxazol-2-yl]benzyl}-6-methoxy-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Synthesis of Both Enantiomers of Protoberberines via Laterally Lithiated (S)-4-Isopropyl-2-(o-tolyl)oxazolines

  摘要：

  DOI：

  10.3987/com-07-s(w)56
• 作为产物：
  描述：

  N-[2-(4-isopropoxy-3-methoxyphenyl)ethyl]formamide 在 三氯氧磷 作用下， 以 乙腈 为溶剂， 反应 0.75h， 以2.35 g的产率得到7-isopropoxy-6-methoxy-3,4-dihydroisoquinoline
  参考文献：
  名称：

  Synthesis of Both Enantiomers of Protoberberines via Laterally Lithiated (S)-4-Isopropyl-2-(o-tolyl)oxazolines

  摘要：

  DOI：

  10.3987/com-07-s(w)56

文献信息

• Antitumoral analogs of lamellarins
  申请人：Pharma Mar, S.A.U.

  公开号：EP2138496A1

  公开（公告）日：2009-12-30

  New lamellarins are provided of the general formula III : wherein X is selected from the group consisting of N, O and S; wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described in the claims and the dotted line represents a single or double bond; or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.

  提供了通式 III 的新型片层蛋白： 其中 X 选自 N、O 和 S 组成的组； 其中 R1、R2、R3、R4、R5、R6、R7、R8 和 R9 如权利要求所述，虚线代表单键或双键； 或其药学上可接受的盐、衍生物、原药或立体异构体。
• Synthesis and antihypertensive activity of a series of spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one]s
  作者：Joan M. Caroon、Robin D. Clark、Arthur F. Kluge、Chi Ho Lee、Arthur M. Strosberg

  DOI：10.1021/jm00364a013

  日期：1983.10

  The 2R*,11bS* and 2S*,11bS* diastereoisomers of the spiro[1,3,4,6,7,11b-hexahydro-2H-benzo[a]quinolizine-2, 5'-oxazolidin-2'-one] system were prepared by stereoselective methods. Evaluation of these compounds for antihypertensive activity by oral administration to the spontaneously hypertensive rat showed the 2S*,11bS* series was the more potent. Within that series it was found that small alkyl substituents at positions 3 and 4' enhanced antihypertensive activity and that methoxyl substitution at positions 9 and 10 was optimal. (2S,3S,11bS)-Spiro-[2-ethyl-9,10-dimethoxy-1,3,4,6,7, 11b-hexahydro-2H-benzo[a]quinolizine-2,5'-oxazolidin-2'-one] [(-)-9e] was one of the most efficacious compounds of this series, while its antipode, (+)-9e, was inactive. Selected compounds in this series were shown to be alpha-adrenoceptor antagonists.
• ANTITUMORAL ANALOGS OF LAMELLARINS
  申请人：Pharma Mar, S.A.U.

  公开号：EP1551844A2

  公开（公告）日：2005-07-13
• US7396837B2
  申请人：——

  公开号：US7396837B2

  公开（公告）日：2008-07-08
• [EN] ANTITUMORAL ANALOGS OF LAMELLARINS<br/>[FR] ANALOGUES ANTITUMORAUX DE LAMELLARINES
  申请人：PHARMA MAR SAU

  公开号：WO2004014917A2

  公开（公告）日：2004-02-19

  New lamellarins are provided of the general formula III wherein X is selected from the group consisting of N, O and S; wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from the group consisting of H, OH, OR’, SH, SR’, SO2R’, NHR’, N(R’)2, N=R', NHCOR', N(COR’)2, NHS02R’, N02, PO(R’2, P02R', C(=0)H, C(=0)R', C02H, C02R’, OPO(R’)2, OP02R', OC(=0)H, OC(=0)R’, N=C(R')2, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C1-C12 haloalkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted heteroaromatic; wherein each of the R' groups is independently selected from the group consisting of H, OH, N02, NH2, SH, CN, halogen, =0, C(=0)H, C(=O)CH3, C02H, C(=0)R', substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-C18 alkoxyl, substituted or unsubstituted C1-C18 aminoalkyl, substituted or unsubstituted C1-C18 aminoacid, substituted or unsubstituted C1-C18 thioalkyl, substituted or unsubstituted C1-C18 alkylsulfinyl, substituted or unsubstituted C1-C18 alkylsulfonyl; wherein the pairs of groups R1 and R2, R2 and R3, R3 and R4, R3 and R9, R4 and R9, R9 and R5, R9 and R6, or R6 and R7, R7 and R8 may be joined into a carbocyclic or heterocyclic ring system; and the dotted line represents an single or double bond; or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof.